Using Large-Scale Data, AI to Assess Effective Migraine Treatment Options: Chia-Chun Chiang, MD
The associate professor of neurology at Mayo Clinic Rochester provided perspective on a new study presented at the 2023 AAN Annual Meeting assessing the treatment effectiveness of real-world patients with migraine. [WATCH TIME: 4 minutes]
WATCH TIME: 4 minutes
"In this study, we employed a generalized linear mixed model, specifically a two-level nested logistic regression model, which can be considered a type of machine learning approach as well. But in the future, there are certainly a lot of different types of machine learning applications and AI applications that can be used in this type of data."
Over the years, the toolbox of therapeutic options for patients with migraine has grown exponentially, headlined by recent calcitonin gene-related peptide (CGRP) antagonists. Using a big-data approach, a recently conducted study simultaneously compared patient-reported treatment effectiveness of 25 acute migraine medications. Across 7 classes of acetaminophen, nonsteroidal anti-inflammatory drugs, triptans, combination analgesics, ergots, anti-emetics, and opioids, 10,842,795 migraine attacks were extracted for data.
Presented at the
Chiang, an associate professor of neurology at
REFERENCE
1. Chiang C, Fang X, Horvath Z. et al. Simultaneous comparisons of 25 acute migraine medications: a big data analysis of 10 million patient self-reported treatment records from a migraine smartphone application. Presented at: 2023 AAN Annual Meeting; April 22-27; Boston, MA. 002258
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.